Eucrates Biomedical Acquisition Corp. (EUCR) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Eucrates Biomedical Acqui...

    NASDAQ: EUCR · Real-Time Price · USD
    10.04
    0.00 (0.00%)
    At close: Apr 26, 2023, 9:14 PM

    Eucrates Biomedical Acquisition Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2022 FY 2021
    Period Ending Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a
    Cost of Revenue
    		 n/a n/a
    Gross Profit
    		 n/a n/a
    Operating Income
    		 -699K -743K
    Interest Income
    		 701.13K 35.76K
    Pretax Income
    		 2.42M 3.82M
    Net Income
    		 5.54M 3.82M
    Selling & General & Admin
    		 n/a 743.07K
    Research & Development
    		 n/a n/a
    Other Expenses
    		 698.58K n/a
    Operating Expenses
    		 698.58K 743.07K
    Interest Expense
    		 n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a
    Cost & Expenses
    		 698.58K 743.07K
    Income Tax Expense
    		 -3.12M -35.76K
    Shares Outstanding (Basic)
    		 2.98M 2.98M
    Shares Outstanding (Diluted)
    		 2.98M 13.46M
    EPS (Basic)
    		 1.86 1.28
    EPS (Diluted)
    		 1.86 0.28
    EBITDA
    		 -2.58M -5.28M
    EBIT
    		 -699K -743K
    Depreciation & Amortization
    		 -1.88M -4.53M

    Add to Watchlist